27 results on '"Thrombocytopenia -- Care and treatment"'
Search Results
2. Keymed Biosciences Announced Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
3. HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
4. Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
5. Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
6. Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain
7. HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
8. Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
9. HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
10. HUTCHMED (China) Limited: VOLUNTARY ANNOUNCEMENT HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia (Stock Code: 13)
11. Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
12. CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
13. Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
14. CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
15. Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia
16. CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia
17. Rigel Announces Post-hoc Data Analysis of TAVALISSE(r) in Adult Patients with Immune Thrombocytopenia Published in the British Journal of Haematology
18. Chemotherapy-Induced Thrombocytopenia (CIT) Pipeline Insight, 2020
19. Shionogi Announces Launch of Mulpleo(r) (lusutrombopag) in the UK, for the Treatment of Severe Thrombocytopenia in Adult Patients With Chronic Liver Disease Undergoing Invasive Procedures
20. Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
21. Nplate(r) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
22. CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
23. Dova Pharmaceuticals Receives Positive Opinion from CHMP for DOPTELET(r) (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
24. Argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
25. Shionogi Announces U.S. Availability of Mulpleta(R) (Lusutrombopag) for the Treatment of Thrombocytopenia in Adults with Chronic Liver Disease
26. argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
27. Ligand Pharmaceuticals Incorporated gets priority review for supplemental NDA for Promacta for thrombocytopenia in adult patients with chronic hepatitis C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.